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INTRODUCTION 
Methods for reducing opiate use and providing satisfactory pain control after 
Cesarean include: 
• Different anesthesia delivery techniques (TAP block, intrathecal morphine, 
and wound infiltration), 
• Different medications or formulations (0.25% bupivacaine, tramadol, 
liposomal bupivacaine), and 
• Changing institutional opiate prescribing guidelines to achieve desired 
results. 
Liposomal bupivacaine (LB; Exparel 1.3%) is an extended-release, local
anesthetic administered perioperatively for management of postoperative  
pain. 
When used as a liposomal suspension, bupivacaine has a fast onset of action 
with a duration up to 72 hours.  
AIM 
To compare the anesthetic methods of wound infiltration and TAP using 
liposomal bupivacaine against the standard of care, postoperative opiates in 
their effectiveness at controlling pain and reducing opiate use after 
Caesarean by comparing pain scores, amount of opiates used post-op, the 
effect of tubal ligation on medication used and the  impact of education level
and previous substance abuse history. 
METHODS 
• Retrospective study of 402 medical records of women delivering by 
Caesarean from January 2018 - January 2019 at a rural hospital in 
southern Ohio. 
• Grouped based on peri-operative anesthesia type-routine spinal (served 
as control), wound infiltration with liposomal bupivacaine (LB INF), and 
TAP with liposomal bupivacaine (LB TAP). 
• All women received scheduled acetaminophen and NSAIDs but opiates 
were only given when requested. 
• Data was collected on the amount of pain medication taken post-
operatively (measured as morphine milligram equivalents (MME)) and 
daily pain scores. 
• The effect of a tubal ligation and history of substance abuse were analyzed 
to determine their impact on pain, opiate use and hospital stay length. 
CONCLUSIONS 
LB infiltration and LB TAP significantly reduced the amount of pain medication 
used post-Cesarean compared to the SOC group and resulted in  lower pain 
scores compared to the SOC group. 
A tubal ligation had no effect on pain medication or pain scores whereas a 
substance abuse history was associated with more opiate use, higher pain 
scores and longer hospital stays. 
Patients who only graduated from high school or less took more opiates 
RESULTS 
• Groups- similar for race, primary Cesarean delivery, tubal ligation 
performed at the time of surgery, and history of substance use. 
• Groups differed on highest level of education with fewer college 
graduates in the SOC group. 
• Education level was used as a covariate in the analyses for MME and 
pain scores. (Table 1). 









Maternal age 25.7±5.5 26.8±5.6 27.4±5.6 <.08 
Race ns 
African American 1.8% (2) 0.5% (1) 2.8% (3)
Caucasian 97.3% (107) 97.8% (180) 97.2% (104)




11th grade 20.9% (23) 10.4% (19) 5.6% (6)
High school 56.4% (62) 46.4% (85) 52.3% (56)
Technical School 5.5% (6) 3.8% (7) 1.9% (2)
College 17.3% (19) 39.3% (72) 40.2% (43)
History of substance
use 
26.4% (29) 23.0% (42) 23.4% (25) ns 
History of opiate use 51.7% (15) 45.2% (19) 48.0% (12) ns[MR1]
Primary Cesarean 56.9% (62) 45.7% (84) 57.9% (62) <.07 
Tubal ligation at time
of surgery 
22.7% (25) 32.4% (60) 32.7% (35) ns 
• Both the LB infiltration and LB TAP groups had significantly lower total MME 
and average MME per day than the SOC group  (Table 2) 
• Patient reported pain scores on POD0 were lower in the LB infiltration group, 
while pain scores on POD1 were lower in both LB infiltration and LB TAP groups 
than in the SOC group. 
• For patients who remained in the hospital on POD2 (n=172), the difference in 
pain scores was not significant, although the LB infiltration group continued to 
report the lowest pain scores. 
• Total opiates used did not differ for patients who had a tubal ligation at the 
time of surgery versus those who did not have a tubal ligation (t= -0.60; p< 
.56). 
• Patient reported pain scores for POD0, POD1, and POD2 were not different for 
women who had a tubal ligation at the time of surgery versus those who did 
not have a tubal ligation (POD0: t= -0.74; p<.46; POD1: t= -0.24; p<.81; & 
POD2: t= -0.67; p<.51). 
Table 2. Primary and Secondary Outcomes by Anesthesia Type. 
SOC LB LB TAP p 
(n=110) Infiltration (n=107) 
Outcome (n=185) 




25.5±51.5 b 24.9±42.2 
b 
<.001 




9.8±18.9 b 9.9±15.6 b <.001 
Percent of women with 0 
MME 
0 55.1% (102) 42.1%
(45) 
<.001 
Patient reported pain – POD0
* 
5.9±1.5 b 4.6±1.7 a 5.5±1.6 b <.001 
Patient reported pain – POD1
* 
6.3±1.4 a 5.3±1.7 b 5.6±1.7 b <.004 
Patient reported pain – POD2
* 
6.3±1.6 5.5±1.7 5.7±1.9 <.30 
Length of stay (days) 2.5±0.5 a 2.4±0.5 b 2.3±0.5 b <.02 
* Analyses included education level as a covariate. 
(a) denotes the group that was significantly different from the other 
group/s (b).
• Patients with a history of substance use had higher amounts of opiate 
use regardless of anesthesia group .  (See Table 3)
• Patients with a history of substance use also reported higher pain scores
at all timepoints regardless of anesthesia group with one exception for 
the SOC group on POD2. 
• Average length of stay for women with a history of substance use 
(2.6±0.6) was significantly higher than for women without a history of 
substance use (2.3±0.5; p<.001). Women with a history of substance 
abuse were more likely to leave the hospital after POD2 (62.5%) than 
women without a history of substance use who were more likely to 
leave the hospital after POD1 (61.5%; p<.001).
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LB TAP p 
Total opiate use (MME) SU: < .001 
No History of SU 59.7±20.4 19.5±40.0 22.0±40.3 Anes: <.001 
Has History of SU 77.2±30.0 44.9±76.5 34.4±47.3 SU x Anes: <.55 
Average opiates used
per day (MME) 
SU: < .03 
Anes: <.001 
No History of SU 24.3±7.9 8.0±16.2 8.9±15.0 SU x Anes: <.73 
Has History of SU 29.7±9.1 15.8±25.5 13.3±17.3 
Percent of women with Anes: <.001 
0 MME 0 73.9% (17) 26.1% (6) SU (Infilt): <.02 
No History of SU 0 68.3% (84) 31.7% (39) SU (TAP): <.03 
Has History of SU 
Pain scores – POD0 SU: < .001 
No History of SU 5.7±1.6 4.3±1.6 5.1±1.4 Anes: <.001 
Has History of SU 6.6±1.3 5.8±1.7 6.7±1.8 SU x Anes: <.31 
Pain scores – POD1 SU: < .001 
No History of SU 6.1±1.5 5.1±1.6 5.3±1.6 Anes: <.01 
Has History of SU 6.7±1.3 6.3±1.5 6.4±1.8 SU x Anes: <.001 
Pain scores – POD2 SU: < .01 
No History of SU 6.3±1.7 5.2±1.6 5.3±1.7 Anes: <.28 
Has History of SU 6.1±1.4 6.4±1.5 6.5±2.0 SU x Anes: <.05 
Length of Stay SU: <.001 
No History of SU 2.5±0.5 2.3±0.5 2.3±0.5 Anes: <.15 
Has History of SU 2.6±0.5 2.6±0.5 2.6±0.6 SU x Anes: <.52 
SU: Substance use main effect; Anes: Anesthesia group main effect; SU x Anes: Substance Use by 
Anesthesia group interaction effect 
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